ReNeuron has announced positive pre-clinical data on its ExoPr0 exosome therapy. The data highlights the potential of ExoPr0 as an anti-cancer therapy and builds on the pre-clinical data announced in May. ReNeuron continues to expect to file for its first clinical trial with ExoPr0 targeting solid tumours within the next eighteen months. ReNeuron has a busy six months ahead with multiple events from its clinical pipeline. We anticipate IND approval to commence a Phase III trial in stroke before ....
09 Oct 2017
N+1 Singer - ReNeuron Group - Positive pre-clinical data with ExoPr0
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - ReNeuron Group - Positive pre-clinical data with ExoPr0
ReNeuron Group plc (RENE:LON) | 3.0 0 0.0% | Mkt Cap: 1.74m
- Published:
09 Oct 2017 -
Author:
Sheena Berry -
Pages:
3
ReNeuron has announced positive pre-clinical data on its ExoPr0 exosome therapy. The data highlights the potential of ExoPr0 as an anti-cancer therapy and builds on the pre-clinical data announced in May. ReNeuron continues to expect to file for its first clinical trial with ExoPr0 targeting solid tumours within the next eighteen months. ReNeuron has a busy six months ahead with multiple events from its clinical pipeline. We anticipate IND approval to commence a Phase III trial in stroke before ....